AbbVie considers ending Shire acquisition deal

AbbVie is considering scrapping the planned £32.4 billion acquisition of Shire drugmaker in what would be the biggest casualty of the US crackdown on so-called tax inversions.

15th October, 2014
Shire stock had dropped to 29 per cent at 8:12 a.m. in London

AbbVie is considering scrapping the planned £32.4 billion acquisition of Shire drugmaker in what would be the biggest casualty of the US crackdown on so-called tax inversions.

Shire’s stock plummeted the most in 12 years after AbbVie said its board will meet on October 20 to reconsider its recommendation that shareholder approve the deal.

AbbVie expected to lower its tax burden by buying the Dublin-based Shire and moving its legal address to the UK. In...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 6 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 6 years ago